ClinicalTrials.gg
CompletedNCT01742663Updated Jan 22, 2014

A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® Gel 3% in the Treatment of Actinic Keratosis

A Phase 1 interventional study of Diclofenac Sodium Gel 3% and Solaraze® (diclofenac sodium) Gel 3% in Actinic Keratosis, sponsored by Taro Pharmaceuticals USA. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-01-22.

Sponsored by Taro Pharmaceuticals USA (part of Sun Pharmaceutical Industries Limited) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
435
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Keratosis, Actinic by Sun Pharmaceutical Industries Limited — 3 open to participants now, 3 under way, 2 of them phase 3. Keratosis, Actinic · Sun Pharmaceutical Industries Limited.

Enrollment
2nd of 15
435 · median 160
Started
2012
the only one that year
Phase 1
4 of 16
1 open now
Registered
5th of 16
by date

Among the 16 studies in Keratosis, Actinic by Sun Pharmaceutical Industries Limited, this one is the 2nd largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2012, is one of 4 in phase 1, and was the 5th registered.

Keratosis, Actinic

343 studies on the registry are indexed under Keratosis, Actinic; 29 are open to participants now.

Browse Keratosis, Actinic studies →

Open to participants now

3 of the 16 studies in Keratosis, Actinic by Sun Pharmaceutical Industries Limited are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 21 Keratosis, Actinic studies recruiting now, 16 (76%) set no upper age limit and 1 (5%) stops at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Keratosis, Actinic by Sun Pharmaceutical Industries Limited, or all of them as a file.
02

Study summary

The objective of this study is to compare the relative efficacy and safety of the test formulation diclofenac sodium gel 3% (Taro Pharmaceuticals Inc.) to the marketed formulation Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms) in the treatment of actinic keratosis.

Both the test and reference formulations will also be compared to a placebo formulation to test for superiority.

03

Conditions studied

  • Actinic Keratosis

Browse trials for

Keywords

  • Diclofenac Sodium Gel 3%
  • Solaraze® (diclofenac sodium) Gel 3%
  • Actinic Keratosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed form.
  • Immunocompetent male or non-pregnant, non-lactating female at least 18 years of age.
  • Diagnosis of AK with at least 5 and no more than 10 clinically typical, visable, discrete, nonhyperkeratotic, nonhypertrophic AK lesions each at least 4 mm in diameter on the face and/or bald scalp contained within a 25 cm2 treatment area.
  • Women either must be 1 year , surgically sterile, or if they are of they must have been using systemic , IUD or Norplant for at least 28 days prior to treatment start, or used barrier methods consistently at least 14 days before study gel administration, had a normal menstrual cycle for the month prior to the start of treatment, have a negative urine pregnancy test result upon entry into the study and agree to use a medically accepted form of birth control throughout the study period.
  • Free from any systemic or dermatologic disorder that, in the opinion of the investigator, will interfere with the study results or increase the risks of AEs.
  • Any skin type or race, providing the skin pigmentation will allow discernment of erythema.
  • Willingness and capability to cooperate to the extent and degree required by the protocol.

Exclusion criteria

Exclusion Criteria:

  • Active gastrointestinal ulceration or bleeding.
  • Current or history of severe renal or hepatic impairment.
  • Presence of atopic dermatitis, basal cell carcinoma, squamous cell carcinoma, eczema, psoriasis, rosacea, sunburn or other possible confounding skin conditions on the face or bald scalp.
  • Use within six months prior to randomization of oral isotretinoin.
  • Use within six months prior to baseline on the face or bald scalp of chemical peel, dermabrasion, laser abrasion, PUVA therapy or UVB therapy.
  • Use within one month prior to baseline on the face or bald scalp of cryodestruction or chemodestruction, curettage, photodynamic therapy, surgical excision, topical 5-fluorouracil, topical , topical diclofenac, topical Imiquimod, topical retinoids or other treatments for actinic keratosis including glycolic acids or over-the-counter products containing retinol, alpha or beta hydroxy acids.
  • Use within one month prior to baseline of immunomodulators or therapies, interferon, systemic corticosteroids or cytotoxic drugs.
  • Known allergies to diclofenac sodium, benzyl alcohol, polyethylene glycol monomethyl ether 359, hyaluronate sodium or any in the test or reference gels.
  • Receiving 5-Fluorouracil or other systemic cancer chemotherapy within 6 months prior to study entry.
  • Any condition, medical, psychological or social, that, in the investigator's opinion, would interfere with participation in the study.
  • Women who are pregnant or planning pregnancy or lactating during the study.
  • Participation in any drug study within 30 days of enrollment or previous participation in this study.
  • Employees or family members of employees of the research center or investigator.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
435 participants (actual)

Study arms

  • Experimental
    Diclofenac Sodium Gel 3%

    Diclofenac Sodium Gel 3% (Taro Pharmaceuticals Inc.)

    Drug: Diclofenac Sodium Gel 3%

  • Active comparator
    Solaraze® (diclofenac sodium) Gel 3%

    Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms)

    Drug: Solaraze® (diclofenac sodium) Gel 3%

  • Placebo comparator
    Vehicle Topical Gel

    Vehicle Topical Gel (Taro Pharmaceuticals Inc.)

    Drug: Vehicle Topical Gel

Interventions

  • Diclofenac Sodium Gel 3% (Taro Pharmaceuticals Inc.) applied twice daily for 60 days.

  • Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms)applied twice daily for 60 days.

  • DrugVehicle Topical Gel

    Vehicle Topical Gel (Taro Pharmaceuticals Inc.) applied twice daily for 60 days.

06

What researchers measure

Primary outcomes

  1. Bioequivalence

    Bioequivalence will be determined by evaluating the proportion of patients in the test and reference groups with 100% clearance of all AK lesions in the treatment area.

    Time frame: Study day 90 (30 days after completion of 60 days of treatment)

Secondary outcomes

  1. Superiority to placebo

    The superiority of the test and reference gels against the placebo will be tested by the proportion of patients showing 100% clearance of actinic keratosis lesions at Day 90 (30 days after completion of 60 days of treatment)using the modified intent to treat population and last observation carried forward.

    Time frame: Study day 90 (30 days after completion of 60 days of treatment)

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2012, a primary completion of Jul 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2012
First posted
Dec 5, 2012
Start
Oct 2012
Primary completionActual
Jul 2013
CompletionActual
Oct 2013
Last update
Jan 22, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01742663
Responsible party
Sponsor
First posted
Dec 5, 2012
Start date
Oct 2012
Primary completion
Jul 2013
Completion
Oct 2013
Last update
Jan 22, 2014

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diclofenac Sodium Gel

Start the discussion